25.30
0.00%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pharmosa Biopharm
Its shares trade on Taipei Exchange under the ticker 6875.TWO. It has been listed since 22 February 2022. In the fiscal year to 31 December 2025, it reported revenue of TWD 67.3m and a net loss of TWD 383.8m. At that date it held total assets of TWD 1.75bn and shareholders' equity of TWD 1.56bn.
Pharmosa Biopharm, Inc. engages in research and development, research, and sale of innovative drugs and medical equipment. The company is headquartered in Taipei City, Taipei. The company went IPO on 2022-02-22. The main products include L606, for the treatment of Category I pulmonary arterial hypertension (PAH); L606, for the treatment of Category III pulmonary hypertension caused by interstitial lung disease (PH-ILD); L606, for the treatment of chronic thromboembolic Category IV pulmonary hypertension (CTEPH); L608, for the treatment of Category I pulmonary arterial hypertension (PAH).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 22 Feb 2022
- Employees
- 39
- Website
- pharmosa.com.tw ↗
Leadership
Pay as last reported
- Mr. Jerry WangChairman of the Board, since 2016
- Mr. Pei KanGeneral Manager, Director, since 2018
- Ms. Ruyun LinDeputy General Manager
- Mr. Hui-An PaoDeputy General Manager-Operations Division
- Weiling ShiCorporate Governance Officer
- Ms. Winny YangSenior Head of Finance & Accounting
- Mr. Siegfried GschliesserDirector
- Mr. Qiheng JianDirector
- Mr. Dejun KongDirector
- Mr. Wen-Hsu YenDirector
- Mr. Wen-Chang ChangIndependent Director
- Ms. Yen-Ling FangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Pharmosa Biopharm Inc develops innovative drugs and medical equipment for global markets.
- The company focuses on L606 for treating Category I pulmonary arterial hypertension.
- L608 targets Category I pulmonary arterial hypertension to expand therapeutic options.
Weaknesses
- The firm employs only 39 full-time staff members in Taipei City.
- Pharmosa Biopharm Inc has a very small operational workforce compared to peers.
- Limited human resources may constrain rapid expansion of research and development activities.
Opportunities
- L606 addresses Category III pulmonary hypertension caused by interstitial lung disease.
- The company can treat Category IV pulmonary hypertension with L606 for CTEPH.
- Expanding sales of L608 could capture more patients with pulmonary arterial hypertension.
Threats
- Pharmosa Biopharm Inc listed its shares on 22 February 2022 recently.
- Small employee count of 39 limits operational resilience against market shocks.
- Focus on specific pulmonary diseases restricts diversification into broader health care segments.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.